Partnership to advance customized biomarker assays for range of neurological conditions
Click Here to Manage Email Alerts
ADx NeuroSciences and Alamar Biosciences have announced a partnership to develop customized biomarker assays for companies that advance novel therapeutics for a range of neurological conditions.
The biomarker assays will be formulated by utilizing Alamar’s Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) immunoassay platform and ARGO HT System, according to a press release from ADx NeuroSciences.
“Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs,” Koen Dewaele, CEO of ADx NeuroSciences, said in the release, "By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it enforces our capabilities to support our pharma network in their search for tailor-made biomarkers."
Terms of the partnership stipulate that ADx and Alamar will agree to pool each company’s expert knowledge toward crafting tailored assays according to the specific needs of pharmaceutical companies that develop novel therapeutics for conditions such as Alzheimer’s disease, Parkinson’s disease and ALS.
"We are excited to partner with ADx NeuroSciences, a recognized leader in the field of neurodegenerative biomarker research," Yuling Luo, PhD, chairman and CEO of Alamar Biosciences, said in the release. "We aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease-modifying therapies for neurodegenerative diseases.”